Now that David Hung is heading up Axovant Sciences Ltd., the high-profile CEO's drug development career seems to be coming full circle, since Medivation Inc. got its start by developing dimebon in partnership with Pfizer Inc. for Alzheimer's disease.
Axovant's future hinges on the Phase III results for its Alzheimer's disease therapy intepirdine, due in September. Hung's ambitions for Axovant involve building the firm into a premier neurology company – much in the same way Medivation had become a leading prostate cancer company before being sold to Pfizer for $14bn last year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?